- Report
- February 2023
- 205 Pages
North America
From €3072EUR$3,450USD£2,655GBP
- Report
- February 2023
- 192 Pages
Asia Pacific
From €3072EUR$3,450USD£2,655GBP
- Report
- February 2023
- 205 Pages
Africa, Middle East
From €3072EUR$3,450USD£2,655GBP
- Report
- December 2022
- 267 Pages
Global
From €3962EUR$4,450USD£3,424GBP
- Report
- August 2022
- 172 Pages
From €3072EUR$3,450USD£2,655GBP
- Report
- August 2022
- 198 Pages
Europe
From €3072EUR$3,450USD£2,655GBP
- Report
- August 2023
- 150 Pages
Global
From €3428EUR$3,850USD£2,962GBP
€4318EUR$4,850USD£3,732GBP
- Report
- August 2022
- 116 Pages
Global
From €4006EUR$4,500USD£3,462GBP
- Report
- December 2024
- 150 Pages
Global
From €2989EUR$3,358USD£2,583GBP
€3517EUR$3,950USD£3,039GBP
- Report
- October 2024
- 99 Pages
Global
From €3500EUR$4,211USD£3,131GBP
- Report
- July 2024
- 132 Pages
Global
From €846EUR$950USD£731GBP
The Sepsis Test market is a subset of the Diagnostics industry, focused on the detection and diagnosis of sepsis. Sepsis is a life-threatening condition caused by the body's response to an infection, and early diagnosis is critical for successful treatment. Sepsis tests are used to detect the presence of sepsis-causing bacteria in the blood, and to identify the type of bacteria present. Tests may also be used to monitor the progress of treatment.
Sepsis tests are typically performed in a laboratory setting, and may include blood cultures, urine cultures, and other tests. Tests may also be performed using point-of-care devices, which allow for rapid diagnosis in the clinical setting.
Companies in the Sepsis Test market include Abbott, Becton Dickinson, bioMérieux, Cepheid, DiaSorin, and Roche. Show Less Read more